Introduction to Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a premier biotechnology company headquartered in Tarrytown, New York, dedicated to inventing life-transforming medicines for serious diseases. Founded in 1988, Regeneron has grown into a global powerhouse with over 13,000 employees and a market capitalization exceeding $80 billion. The company is widely recognized for its innovative approach to drug discovery, particularly through its proprietary VelociSuite technologies, which accelerate the development of fully human antibodies and gene-edited models. Regeneron’s commercial portfolio includes blockbuster drugs such as EYLEA (aflibercept) for ophthalmology, Dupixent (dupilumab) for atopic diseases, and Libtayo (cemiplimab) for oncology, collectively generating over $13 billion in annual revenue. The company’s scientific excellence and robust pipeline in immunology, oncology, and rare diseases have earned it a top-tier reputation among investors, healthcare providers, and patients worldwide. As a leader in the Healthcare industry, Regeneron consistently ranks among the most admired companies in Fortune’s World’s Most Admired Companies list and is a frequent recipient of R&D awards. Organizations ranging from academic medical centers to government agencies rely on Regeneron for cutting-edge therapies, collaborative research, and contract development services. This comprehensive profile delves into every facet of Regeneron Pharmaceuticals, Inc., from its founding story to its future roadmap, workplace culture, and the specific opportunities available for top-tier talent.
Company History and Business Evolution
Regeneron Pharmaceuticals, Inc. was founded in 1988 by Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., with a vision to leverage genetic insights into drug discovery. The early years were marked by pioneering research in receptor biology, leading to the first approved therapy, Arcalyst (rilonacept), for cryopyrin-associated periodic syndromes (CAPS) in 2008. However, the company’s major inflection point came with the development of VelocImmune, a genetically engineered mouse that produces fully human antibodies, drastically reducing development timelines. This technology yielded the blockbuster drug Dupixent, approved in 2017 for atopic dermatitis, and later for asthma, nasal polyps, and eosinophilic esophagitis. Regeneron’s expansion continued through strategic acquisitions, such as the purchase of the manufacturing facility in Limerick, Ireland, and partnerships with Sanofi, Bayer, and Alnylam. In 2020, the company gained global recognition for REGEN-COV (casirivimab and imdevimab), an antibody cocktail for COVID-19, which was developed in record time using VelociSuite. The company also invests heavily in gene editing and gene therapy, with a pipeline targeting rare genetic diseases. Over three decades, Regeneron has evolved from a small research lab into a vertically integrated biopharmaceutical giant with state-of-the-art manufacturing, clinical development, and commercial capabilities. The company’s history is a testament to the power of sustained investment in basic science and a commitment to translating genetic discoveries into medicines.
Regeneron Pharmaceuticals, Inc. at a Glance
- Headquarters: Tarrytown, New York, USA
- Founded: 1988
- Founders: Leonard S. Schleifer, George D. Yancopoulos
- CEO: Leonard S. Schleifer
- CSO: George D. Yancopoulos
- Industry: Biotechnology / Biopharmaceuticals
- Revenue: $13.6 billion (2023)
- Employees: Over 13,000 globally
- Flagship Products: EYLEA, Dupixent, Libtayo, Praluent, Inmazeb, REGEN-COV
- Key Technology: VelociSuite (VelocImmune, VelocGene, VelocCell, VelocTarg)
- Global Presence: Operations in 20+ countries, manufacturing in USA, Ireland, Netherlands
- Stock Symbol: REGN (Nasdaq)
- Research Focus: Immunology, Oncology, Ophthalmology, Cardiovascular, Rare Diseases
- Notable Partnerships: Sanofi, Bayer, Alnylam, Incyte
- Regulatory Milestones: 7 FDA-approved products as of 2024
- Awards: Fortune World’s Most Admired Companies, AAAS Fellows, Prix Galien
- Community Engagement: Regeneron Science Talent Search, STEM education, patient assistance programs
- Pipeline: 35+ clinical programs in Phase 1-3
- Market Cap: ~$80 billion
- Sustainability: Committed to carbon neutrality, green chemistry initiatives
Mission, Vision, and Core Corporate Values
Regeneron Pharmaceuticals, Inc. operates with a mission to invent life-transforming medicines by harnessing the power of genetics and cutting-edge science. The company envisions a world where serious diseases are no longer serious, driven by a pipeline of innovative therapies that address high unmet medical needs. Core values include scientific excellence, integrity, collaboration, and patient centricity. Regeneron believes in investing in its people, fostering a culture of curiosity and rigor, and maintaining transparency in all interactions. The company’s values are embedded in its research philosophy—rapid translation from genetic discovery to clinical application—and its commitment to ethical business practices, as evidenced by its inclusion in the Dow Jones Sustainability Index. Every decision, from R&D priorities to manufacturing and commercialization, is guided by the principle of improving patient outcomes while ensuring long-term shareholder value.
Business Strategy and Future Roadmap
Regeneron’s business strategy revolves around a robust focus on genetics-first drug discovery, leveraging its proprietary VelociSuite platform to develop first-in-class and best-in-class therapies. The company aims to expand its pipeline in high-growth therapeutic areas such as immunology, oncology, and rare diseases. Key strategic pillars include deepening the portfolio of existing blockbusters (e.g., Dupixent expansion into COPD and CSU), advancing next-generation therapeutics (e.g., bispecific antibodies, gene editing technologies), and maximizing global access through strategic partnerships. Regeneron is also investing in oncology biologics, with programs targeting PD-1, LAG-3, and other immune checkpoints. The future roadmap includes a strong push into gene therapy and CRISPR-based technologies for conditions like hemophilia and inherited retinal diseases. Additionally, the company plans to expand its manufacturing footprint to meet global demand, including a new facility in Dublin. Digital transformation and AI-assisted drug discovery are emerging priorities, with collaborations to integrate machine learning into antibody design. Regeneron’s capital allocation strategy balances substantial R&D reinvestment (over 40% of revenue), share buybacks, and selected acquisitions of complementary technologies.
Products, Technologies, and Services
Regeneron is best known for its innovative therapeutics and proprietary technology platforms. The product portfolio includes:
- EYLEA (aflibercept): An anti-VEGF therapy for wet age-related macular degeneration, diabetic macular edema, and other retinal diseases.
- Dupixent (dupilumab): An IL-4 receptor alpha antagonist for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
- Libtayo (cemiplimab): An anti-PD-1 monoclonal antibody for advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
- Praluent (alirocumab): A PCSK9 inhibitor for hypercholesterolemia (co-developed with Sanofi).
- REGEN-COV (casirivimab + imdevimab): An antibody cocktail for COVID-19 prophylaxis and treatment (EUA now expired, but provided critical data).
- Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn): A three-antibody cocktail for Ebola virus infection.
Technologies include VelocImmune, a genetically engineered mouse platform producing fully human antibodies; VelocGene for targeted gene editing; VelocCell for rapid cell line development; and VelocTarg for target validation. These platforms enable Regeneron to develop antibodies in half the time of traditional methods. The company also offers contract development and manufacturing services (CDMO) through its industrial operations, providing end-to-end biologics production for external partners.
Industries and Markets Served
Regeneron Pharmaceuticals, Inc. primarily serves the global healthcare industry, including pharmaceuticals, biotechnology, and medical research. Its therapies are used by hospitals, clinics, specialty pharmacies, and academic medical centers worldwide. Key therapeutic areas include ophthalmology (EYLEA), immunology and inflammation (Dupixent), oncology (Libtayo), cardiovascular disease (Praluent), rare diseases (Arcalyst), and infectious diseases (Inmazeb, REGEN-COV). The company’s research also extends into metabolic and genetic disorders. Regeneron’s customers include retail and institutional pharmacies, wholesalers, government health agencies like the CDC and BARDA, and clinical trial sites. The company’s influence spans across the entire biopharmaceutical value chain, from drug discovery to patient access.
Leadership and Management Philosophy
Regeneron’s leadership is deeply rooted in scientific expertise. Leonard S. Schleifer, CEO since founding, is a neurologist and trained scientist; George D. Yancopoulos, CSO, is a renowned molecular biologist and inventor of VelociSuite. The executive team blends operational excellence with academic rigor. Management philosophy emphasizes flat organizational structures, open communication, and empowering scientists. Regeneron invests heavily in employee development through in-house training programs, a strong mentorship culture, and opportunities to publish and attend scientific conferences. The company’s leadership principles include data-driven decision-making, long-term thinking, and a bias for action. Regeneron’s board includes industry veterans and independent researchers, ensuring strategic oversight aligned with patient needs.
Corporate Events, Conferences, and Community Engagement
Regeneron actively participates in major scientific and industry conferences such as ASCO, ESMO, AAAIC, and ARVO, where it presents clinical trial results and pipeline updates. The company hosts investor days, webinars, and symposiums. Community engagement includes the Regeneron Science Talent Search, the nation’s oldest and most prestigious science and math competition for high school students, awarding over $3 million annually. Regeneron also funds local STEM education programs in Westchester County, supports patient advocacy groups like the Asthma and Allergy Foundation, and runs international health equity initiatives. In 2023, the company donated over $100 million in medicines and monetary contributions.
Employees and Workplace Culture
With over 13,000 employees, Regeneron fosters a culture of curiosity, collaboration, and urgency. The workplace is characterized by high autonomy and accountability. Employees benefit from competitive compensation, stock options, generous paid time off, and comprehensive health plans. The company has been consistently rated as a Top Employer by Science magazine and frequently appears on Glassdoor’s Best Places to Work. Diversity and inclusion are prioritized through employee resource groups (e.g., Women in Science, PRIDE, Veterans). Regeneron also offers on-site child care, fitness centers, and flexible work arrangements (hybrid for corporate roles, on-site for R&D). The company’s culture is often described as intense but rewarding, with a shared mission to cure disease.
Job Details & Requirements for this Posting
Position Title: Senior Research Scientist, Immunology
Location: Tarrytown, New York (on-site)
Salary Range: $140,000 – $185,000 per year (commensurate with experience) plus bonus and equity
Job Type: Full-time
Responsibilities:
- Lead independent research projects in immunology, focused on identifying new therapeutic targets and developing antibody-based therapies.
- Design, execute, and analyze in vitro and in vivo experiments to validate targets and understand disease mechanisms.
- Mentor and supervise junior scientists and research associates.
- Collaborate cross-functionally with protein engineering, pharmacology, and clinical development teams.
- Present findings at internal meetings and external conferences; publish in high-impact journals.
- Contribute to patent filings and regulatory documentation.
- Stay abreast of scientific literature and emerging technologies to drive innovation.
Qualifications:
- Ph.D. in Immunology, Molecular Biology, or related field with at least 5 years of post-Ph.D. experience (industry or academia).
- Strong track record of peer-reviewed publications.
- Expertise in flow cytometry, ELISA, ELISA-based assays, cell culture, and animal models.
- Experience with antibody discovery and protein engineering is highly desirable.
- Excellent communication, problem-solving, and leadership skills.
- Ability to work in a fast-paced, team-oriented environment.
Why Join Regeneron?
At Regeneron, you will work on groundbreaking science that directly impacts millions of patients. You’ll have access to world-class platforms, collaborate with some of the brightest minds in biotech, and receive generous compensation, including performance bonuses, stock options, and comprehensive benefits. The company offers a clear career progression path and strong support for continuous learning. If you’re passionate about immunology and want to bring life-changing medicines to market, Regeneron is the place for you.
Customer Reviews and Industry Reputation
Regeneron Pharmaceuticals, Inc. enjoys an exceptional reputation across multiple review platforms, reflecting its innovative culture and employee satisfaction. Below is an exhaustive analysis from major sources.
Glassdoor
On Glassdoor, Regeneron holds a 4.2/5 star rating based on over 4,000 reviews. Employees frequently praise the intellectual challenges, supportive teams, and competitive pay. Common positives include "cutting-edge science," "great benefits," and "opportunities for growth." Criticisms sometimes mention long hours and high pressure, especially in R&D roles. 80% of reviewers would recommend Regeneron to a friend, and the CEO approval rating is 90%.
Indeed
Indeed shows a 3.9/5 rating with over 1,500 reviews. Highlights include strong compensation, comprehensive benefits, and collaborative environment. Some reviewers note "siloed departments" and "lack of work-life balance in certain departments." However, the overall sentiment remains positive, with many employees appreciating the mission-driven work.
Gartner Peer Insights
As a biotech company, Regeneron does not typically appear on Gartner Peer Insights (which focuses on IT). However, in the context of pharmaceutical R&D outsourcing, client reviews from partners highlight Regeneron’s reliability, speed, and scientific expertise. NPS scores from customer surveys are consistently above 60.
Trustpilot
Regeneron does not have a dedicated consumer-facing Trustpilot page, as it primarily sells prescription medicines. However, patient advocacy groups and clinical trial participants often share positive testimonials on other health forums, praising the efficacy of Regeneron drugs like Dupixent and Libtayo.
G2
Not applicable for a drug company. Regeneron’s “customers” are healthcare providers and payers, who generally rate the value of therapies high based on outcomes.
Google Reviews
Google reviews for Regeneron’s Tarrytown campus average 4.1/5. Employees and visitors note state-of-the-art facilities, clean environment, and friendly staff. Patients occasionally leave reviews about positive experiences with Regeneron treatments, especially for EYLEA and Dupixent.
LinkedIn Reputation
Regeneron has over 600,000 followers on LinkedIn. The company is frequently featured for scientific achievements, awards, and community engagement. Employee testimonials highlight a strong sense of purpose and pride in work. Industry analysts often cite Regeneron as a bellwether for biotech innovation.
Overall, Regeneron is regarded as a top employer and a trusted therapeutic provider, with high marks for science, compensation, and impact.
Why Organizations Choose Regeneron
Healthcare organizations, research institutions, and government agencies partner with Regeneron for several reasons: unmatched R&D capabilities (fastest antibody discovery), proven track record of regulatory approvals, scalable manufacturing, global reach, and ethical business practices. Regeneron’s commitment to data transparency and patient access programs (e.g., Regeneron Patient Assistance Program) makes it a preferred collaborator. The company’s pipeline depth reduces risk for partners, while its financial stability ensures long-term commitment. In addition, Regeneron’s willingness to co-develop and share risk through innovative licensing deals attracts top-tier biotech and pharma companies.
Official Contact Information
For inquiries and assistance, please reach out to Regeneron Pharmaceuticals, Inc. using the following contact details:
777 Old Saw Mill River Road
Tarrytown, NY 10591, USA
Contact Number: +1-914-847-7000
Support Number: +1-800-828-2080 (Medical Information)
Helpdesk Number: +1-914-847-3400 (HR/Benefits)
Website: www.regeneron.com
Official Social Media Presence
Follow Regeneron on LinkedIn (linkedin.com/company/regeneron-pharmaceuticals), Twitter (@regeneron), Facebook (Regeneron), YouTube (RegeneronOfficial), and Instagram (@regeneron). Stay updated on pipeline news, career opportunities, and scientific breakthroughs.
SEO FAQ Section
1. What is Regeneron Pharmaceuticals, Inc. known for?Regeneron Pharmaceuticals, Inc. is known for inventing life-changing medicines, particularly in immunology, oncology, and ophthalmology, and for its proprietary VelociSuite technologies that accelerate antibody discovery.
2. Where is Regeneron Pharmaceuticals, Inc. headquartered?Regeneron Pharmaceuticals, Inc. is headquartered in Tarrytown, New York, USA.
3. Is Regeneron Pharmaceuticals, Inc. a good company to work for?Yes, Regeneron Pharmaceuticals, Inc. consistently ranks among the top employers in biotechnology, with high scores on Glassdoor for compensation, scientific challenge, and mission.
4. What products does Regeneron Pharmaceuticals, Inc. make?Regeneron Pharmaceuticals, Inc. manufactures EYLEA, Dupixent, Libtayo, Praluent, Inmazeb, and REGEN-COV, among others.
5. How many employees does Regeneron Pharmaceuticals, Inc. have?Regeneron Pharmaceuticals, Inc. employs over 13,000 people globally.
6. Who founded Regeneron Pharmaceuticals, Inc.?Regeneron Pharmaceuticals, Inc. was founded by Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos in 1988.
7. What is the revenue of Regeneron Pharmaceuticals, Inc.?Regeneron Pharmaceuticals, Inc. reported revenue of $13.6 billion in 2023.
8. Is Regeneron Pharmaceuticals, Inc. publicly traded?Yes, Regeneron Pharmaceuticals, Inc. is traded on the Nasdaq under the symbol REGN.
9. What therapeutic areas does Regeneron Pharmaceuticals, Inc. focus on?Regeneron Pharmaceuticals, Inc. focuses on immunology, oncology, ophthalmology, cardiovascular disease, rare diseases, and infectious diseases.
10. What is VelociSuite?VelociSuite is a set of proprietary technologies owned by Regeneron Pharmaceuticals, Inc. that includes VelocImmune and VelocGene, enabling rapid discovery of fully human antibodies and gene-edited models.
11. Does Regeneron Pharmaceuticals, Inc. offer internships?Yes, Regeneron Pharmaceuticals, Inc. offers internships for undergraduate and graduate students in science and business.
12. What is the company culture like at Regeneron Pharmaceuticals, Inc.?The culture at Regeneron Pharmaceuticals, Inc. is science-driven, collaborative, and fast-paced, with a strong emphasis on innovation and patient impact.
13. How does Regeneron Pharmaceuticals, Inc. support the community?Regeneron Pharmaceuticals, Inc. supports the community through the Regeneron Science Talent Search, STEM education, and charitable medicine donations.
14. What are the career paths at Regeneron Pharmaceuticals, Inc.?Career paths at Regeneron Pharmaceuticals, Inc. include research, clinical development, manufacturing, commercial, and corporate functions.
15. Does Regeneron Pharmaceuticals, Inc. have a diverse workforce?Yes, Regeneron Pharmaceuticals, Inc. is committed to diversity and inclusion, with employee resource groups and equal opportunity hiring practices.
16. What is the salary at Regeneron Pharmaceuticals, Inc. for scientists?Salaries at Regeneron Pharmaceuticals, Inc. for scientists are highly competitive, typically ranging from $90,000 to $200,000 depending on experience and role.
17. What benefits does Regeneron Pharmaceuticals, Inc. offer?Regeneron Pharmaceuticals, Inc. offers comprehensive health insurance, retirement plans, stock options, paid parental leave, and on-site amenities.
18. Is Regeneron Pharmaceuticals, Inc. involved in gene therapy?Yes, Regeneron Pharmaceuticals, Inc. has a robust gene therapy pipeline for rare diseases, using adeno-associated virus (AAV) vectors and CRISPR technologies.
19. What is the future outlook for Regeneron Pharmaceuticals, Inc.?The future outlook for Regeneron Pharmaceuticals, Inc. is strong, with a deep pipeline, expansion into new therapeutics, and continued innovation in biologics and gene editing.
20. How can I apply for a job at Regeneron Pharmaceuticals, Inc.?You can apply for jobs at Regeneron Pharmaceuticals, Inc. through their official careers website at www.regeneron.com/careers.
For in-depth corporate profiles and guest posting opportunities, explore industry resources such as the Guest Posting Agency for thought leadership articles. Regeneron Pharmaceuticals, Inc. maintains its official website as a central hub for company news, investor relations, and career information. Additionally, access high-quality backlinks and SEO guest posting services to amplify your content strategy and reach target audiences effectively.
", "location": "Tarrytown, New York", "salary": "$140,000 - $185,000 per year", "job_type": "Full-time" }